Leadership Overview
InnoCare Pharma has 4 executives leading key functions including strategy, finance, medical affairs, and operations.
Driven by scientific innovation, InnoCare Pharma is dedicated to developing first-in-class or best-in-class therapies for global markets, addressing significant unmet clinical needs in oncology and autoimmune diseases.
Driven by scientific innovation, InnoCare Pharma is dedicated to developing first-in-class or best-in-class therapies for global markets, addressing significant unmet clinical needs in oncology and autoimmune diseases.
Leadership Roles at InnoCare Pharma
Nghia Ba - Chief Executive Officer
Nghia Ba, the Chief Executive Officer at InnoCare Pharma, directs the overarching corporate strategy and operational execution. This leadership role involves guiding the company's mission to develop innovative drugs for malignant tumors and autoimmune diseases, ensuring alignment with global market demands. Ba oversees the integration of research and commercialization capabilities, fostering an environment where scientific discovery translates into patient benefit. The Chief Executive Officer's focus remains on advancing the pipeline and securing InnoCare Pharma's position as a leader in delivering high-quality, innovative medicines worldwide. Nghia Ba drives the company's commitment to addressing significant unmet clinical needs through pioneering therapeutic solutions.
Xin Fu - Chief Financial Officer
Xin Fu, the Chief Financial Officer at InnoCare Pharma, manages all financial operations and strategic financial planning. This executive oversees capital allocation, investor relations, and the financial health of the organization, ensuring resources are effectively deployed to support drug development and commercialization efforts. Fu's responsibilities include maintaining robust financial controls and driving fiscal discipline across all departments. The Chief Financial Officer plays a critical part in evaluating investment opportunities and managing the company's financial performance to support its growth objectives in the pharmaceutical sector. Xin Fu ensures the financial stability required for InnoCare Pharma to pursue its mission of creating first-in-class or best-in-class therapies for global patients.
Qiang Zhou - Chief Medical Officer
Qiang Zhou, the Chief Medical Officer at InnoCare Pharma, leads the clinical development and medical affairs strategy. This role is central to advancing the company's pipeline in hematological malignancies, autoimmune diseases, and solid tumors, ensuring that therapeutic candidates meet rigorous clinical standards. Zhou oversees the design and execution of clinical trials, guiding the transition of innovative drug candidates from research to regulatory submission. The Chief Medical Officer's expertise is crucial for identifying and prioritizing significant unmet clinical needs, driving the development of therapies that offer substantial patient benefits. Qiang Zhou ensures InnoCare Pharma's commitment to delivering high-quality, innovative medicines is realized through sound medical and scientific leadership.
Kevin Gao - Chief Operations Officer
Kevin Gao, the Chief Operations Officer at InnoCare Pharma, directs the company's operational infrastructure and execution. This leadership position involves optimizing manufacturing processes, supply chain management, and ensuring the efficient delivery of pharmaceutical products to global markets. Gao oversees the integration of research and commercialization capabilities, translating scientific innovation into tangible patient access. The Chief Operations Officer's focus is on enhancing operational efficiency and scalability to support InnoCare Pharma's ambitious development goals. Kevin Gao ensures that the company's comprehensive capabilities are leveraged effectively to create and deliver best-in-class therapies, reinforcing the commitment to addressing unmet clinical needs worldwide.
Explore Leadership Teams in Manufacturing
Founded in 1994 and headquartered in Shanghai, China, Fosun Pharma is a company that focuses on the research and development and manufacturing of pharmaceuticals.
Company Leadership YB
YS
AH
CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Hong Kong.
Company Leadership CD
CL
CW
QW
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
SP
CS
MD
Founded in 1988 and headquartered in Westbury, New York, PL Developments is a manufacturer, packager, and distributor of pharmaceutical and consumer healthcare products.
Company Leadership AS
CN
AN
MS
Frequently Asked Questions Regarding InnoCare Pharma Top Executives and Leadership Team
